secwatch.observer — SEC 8-K summary
======================================

Issuer:     CytomX Therapeutics, Inc. (CTMX)
CIK:        0001501989
Form:       8-K
Filed at:   2026-07-27T12:05:07+00:00
Accession:  0001193125-26-316929
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

CytomX appoints Charles Fuchs to Board of Directors as Class II director
------------------------------------------------------------------------

- Dr. Fuchs appointed effective July 24, 2026, as Class II director with term expiring at 2029 annual meeting.
- Receives option to purchase 118,000 shares at closing price on appointment date, vesting monthly over 3 years.
- Will receive standard non-employee director compensation and enter into indemnification agreement.
- No material transactions or arrangements between Dr. Fuchs and the Company exceeding $120,000.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501989/000119312526316929/0001193125-26-316929-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501989/000119312526316929/d30807d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-316929

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer